Skip to main content
Top
Published in: Globalization and Health 1/2018

Open Access 01-12-2018 | Research

Psychotropic drugs in Nepal: perceptions on use and supply chain management

Authors: Nawaraj Upadhaya, Mark J. D. Jordans, Dristy Gurung, Ruja Pokhrel, Ramesh P. Adhikari, Ivan H. Komproe

Published in: Globalization and Health | Issue 1/2018

Login to get access

Abstract

Background

Psychotropic drugs play an important role in the treatment of mental, neurological and substance use disorders. Despite the advancement of the use of psycho-pharmaceuticals in the developed countries, the psychotropic drug production and supply chain management in low- and middle- income countries are still poorly developed. This study aims to explore the perceptions of stakeholders involved in all stages of the psychotropic drug supply chain about the need, quality, availability and effectiveness of psychotropic drugs, as well as barriers to their supply chain management.
The study was conducted among 65 respondents from the Kathmandu, Chitwan and Pyuthan districts, grouped into four categories: producers, promoters and distributors (N = 22), policy makers and government actors (N = 8), service providers (N = 21) and service users/family members (N = 14).

Results

The respondents reported that psychotropic drugs, despite having side effects, are 1) needed, 2) available in major regional centers and 3) are effective for treating mental health problems. The stigma associated with mental illness, however, forces patients and family members to hide their use of psychotropic drugs. The study found that the process of psychotropic drug supply chain management is similar to other general drugs, with the exceptions of strict pre-approval process, quantity restriction (for production and import), and mandatory record keeping. Despite these regulatory provisions, respondents believed that the misuse of psychotropic drugs is widespread and companies are providing incentives to prescribers and retailers to retain their brand in the market.

Conclusions

The production and supply chain management of psychotropic drugs is influenced by the vested interests of pharmaceutical companies, prescribers and pharmacists. In the context of the government of Nepal’s policy of integrating mental health into primary health care and increased consumption of psychotropic drugs in Nepal, there is a need for massive education and awareness as well as strict monitoring and supervision to avoid the misuse of psychotropic drugs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Eaton J. Ensuring access to psychotropic medication in sub-Saharan Africa. African Journal of Psychiatry. 2008;113:179–81. Eaton J. Ensuring access to psychotropic medication in sub-Saharan Africa. African Journal of Psychiatry. 2008;113:179–81.
2.
go back to reference Padmanathan P, Singh M, Mannarath SC, Omar M, Raja S. A rapid appraisal of access to and utilisation of psychotropic medicines in Bihar, India. Int J Ment Heal Syst. 2014;81:1. Padmanathan P, Singh M, Mannarath SC, Omar M, Raja S. A rapid appraisal of access to and utilisation of psychotropic medicines in Bihar, India. Int J Ment Heal Syst. 2014;81:1.
3.
go back to reference McBain R, Norton DJ, Morris J, Yasamy MT, Betancourt TS. The role of health systems factors in facilitating access to psychotropic medicines: a cross-sectional analysis of the WHO-AIMS in 63 low-and middle-income countries. PLoS Med. 2012;91:e1001166.CrossRef McBain R, Norton DJ, Morris J, Yasamy MT, Betancourt TS. The role of health systems factors in facilitating access to psychotropic medicines: a cross-sectional analysis of the WHO-AIMS in 63 low-and middle-income countries. PLoS Med. 2012;91:e1001166.CrossRef
4.
go back to reference WHO. Improving access and use of psychotropic medicines. 2005. WHO. Improving access and use of psychotropic medicines. 2005.
5.
go back to reference WHO. Mental Health Gap Action Programme: Scaling up Care for Mental, Neurological and Substance Use Disorder. Geneva: World Health Organization (WHO); 2008. WHO. Mental Health Gap Action Programme: Scaling up Care for Mental, Neurological and Substance Use Disorder. Geneva: World Health Organization (WHO); 2008.
6.
go back to reference Schlosser AV, Ninnemann K. Introduction to the special section: the anthropology of psychopharmaceuticals: cultural and pharmacological efficacies in context. Cult Med Psychiatry. 2012;361:2–9.CrossRef Schlosser AV, Ninnemann K. Introduction to the special section: the anthropology of psychopharmaceuticals: cultural and pharmacological efficacies in context. Cult Med Psychiatry. 2012;361:2–9.CrossRef
7.
go back to reference Helman CG. ‘Tonic’,‘fuel’and ‘food’: Social and symbolic aspects of the long-term use of psychotropic drugs. Soc Sci Med. 1981;15B:521–33. Helman CG. ‘Tonic’,‘fuel’and ‘food’: Social and symbolic aspects of the long-term use of psychotropic drugs. Soc Sci Med. 1981;15B:521–33.
8.
go back to reference Van der Geest S, Whyte SR, Hardon A. The anthropology of pharmaceuticals: a biographical approach. Annu Rev Anthropol. 1996:153–78. Van der Geest S, Whyte SR, Hardon A. The anthropology of pharmaceuticals: a biographical approach. Annu Rev Anthropol. 1996:153–78.
9.
go back to reference Harper I, Rawal N, Subedi M. Disputing distribution: ethics and pharmaceutical regulation in Nepal. Studies in Nepali history and. Society. 2011;16(1):1–39. Harper I, Rawal N, Subedi M. Disputing distribution: ethics and pharmaceutical regulation in Nepal. Studies in Nepali history and. Society. 2011;16(1):1–39.
10.
go back to reference Jordans M, Luitel N, Pokhrel P, Patel V. Development and pilot testing of a mental healthcare plan in Nepal. The British Journal of Psychiatry. 2016;208(s56):s21–8.CrossRefPubMedPubMedCentral Jordans M, Luitel N, Pokhrel P, Patel V. Development and pilot testing of a mental healthcare plan in Nepal. The British Journal of Psychiatry. 2016;208(s56):s21–8.CrossRefPubMedPubMedCentral
11.
go back to reference Semrau M, Evans-Lacko S, Alem A, Ayuso-Mateos JL, Chisholm D, Gureje O, Hanlon C, Jordans M, Kigozi F, Lempp H. Strengthening mental health systems in low-and middle-income countries: the Emerald programme. BMC Med. 2015;131:79.CrossRef Semrau M, Evans-Lacko S, Alem A, Ayuso-Mateos JL, Chisholm D, Gureje O, Hanlon C, Jordans M, Kigozi F, Lempp H. Strengthening mental health systems in low-and middle-income countries: the Emerald programme. BMC Med. 2015;131:79.CrossRef
12.
go back to reference Government of Nepal. Drug Act, 1978.In. Kathmandu, Nepal; 1978. Government of Nepal. Drug Act, 1978.In. Kathmandu, Nepal; 1978.
13.
go back to reference Shrestha P. Policy initiatives for drug control in Nepal. Health. 2011;22:66–8. Shrestha P. Policy initiatives for drug control in Nepal. Health. 2011;22:66–8.
14.
go back to reference Ferrario A, Sautenkova N, Bezverhni Z, Seicas R, Habicht J, Kanavos P, Safta V. An in-depth analysis of pharmaceutical regulation in the Republic of Moldova. Journal of Pharmaceutical Policy and Practice. 2014;71:4.CrossRef Ferrario A, Sautenkova N, Bezverhni Z, Seicas R, Habicht J, Kanavos P, Safta V. An in-depth analysis of pharmaceutical regulation in the Republic of Moldova. Journal of Pharmaceutical Policy and Practice. 2014;71:4.CrossRef
15.
go back to reference Brhlikova P, Harper I, Jeffery R, Rawal N, Subedi M, Santhosh M. Trust and the regulation of pharmaceuticals: South Asia in a globalised world. Glob Health. 2011;71:1. Brhlikova P, Harper I, Jeffery R, Rawal N, Subedi M, Santhosh M. Trust and the regulation of pharmaceuticals: South Asia in a globalised world. Glob Health. 2011;71:1.
16.
go back to reference Banerjee I, Roy B, Sathian B, Banerjee I, Chakraborty PK, Saha A. Socio Demographic profile and utilization pattern of antipsychotic drugs among schizophrenic inpatients: a cross sectional study from western region of Nepal. BMC Psychiatry. 2013;131:1. Banerjee I, Roy B, Sathian B, Banerjee I, Chakraborty PK, Saha A. Socio Demographic profile and utilization pattern of antipsychotic drugs among schizophrenic inpatients: a cross sectional study from western region of Nepal. BMC Psychiatry. 2013;131:1.
17.
go back to reference Sah P, Sah AK, Jha RK. Evaluation of the rationality of psychotropic drug promotional literatures in Nepal. Journal of Drug Delivery and Therapeutics. 2012;2(6):6-8. Sah P, Sah AK, Jha RK. Evaluation of the rationality of psychotropic drug promotional literatures in Nepal. Journal of Drug Delivery and Therapeutics. 2012;2(6):6-8.
18.
go back to reference Adhikari S, Pradhan S, Sharma S. Experiencing stigma: Nepalese perspectives. Kathmandu University medical journal. 2008;6(4):458–65. Adhikari S, Pradhan S, Sharma S. Experiencing stigma: Nepalese perspectives. Kathmandu University medical journal. 2008;6(4):458–65.
19.
go back to reference MoHP. Nepal Health Sector Program Implementation Plan II (NHSP-IP II). Kathmandu: Ministry of Health and Population; 2010. MoHP. Nepal Health Sector Program Implementation Plan II (NHSP-IP II). Kathmandu: Ministry of Health and Population; 2010.
20.
go back to reference Dharmawardene V, Menkes DB. Psychotropic drugs in low-income countries. The Lancet Psychiatry. 2014;17:490–2.CrossRef Dharmawardene V, Menkes DB. Psychotropic drugs in low-income countries. The Lancet Psychiatry. 2014;17:490–2.CrossRef
Metadata
Title
Psychotropic drugs in Nepal: perceptions on use and supply chain management
Authors
Nawaraj Upadhaya
Mark J. D. Jordans
Dristy Gurung
Ruja Pokhrel
Ramesh P. Adhikari
Ivan H. Komproe
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Globalization and Health / Issue 1/2018
Electronic ISSN: 1744-8603
DOI
https://doi.org/10.1186/s12992-018-0322-4

Other articles of this Issue 1/2018

Globalization and Health 1/2018 Go to the issue